MODERN OPPORTUNITIES OF PHARMACOTHERAPY FOR PATIENTS WITH SHORT BOWEL SYNDROME
https://doi.org/10.34822/2304-9448-2021-4-26-30
Abstract
The study aims to detect the main methods and means for modern pharmacotherapy for patients with short bowel syndrome. Material and methods. The search was carried out in the following databases: PubMed, eLibrary, and Clinical Trials, using such keywords as intestinal failure, parental nutrition, short bowel syndrome. Results. Based on the analysis of published works, it was found that the analog of glucagonlike peptide-2, teduglutide, can reduce the parental nutrition, infusion duration, and provide full enteral autonomy, which makes the treatment method with such drug the most promising one for patients with short bowel syndrome.
About the Author
E. V. Sosnovskaya
Khanty-Mansiysk State Medical Academy;
District Clinical Hospital, Khanty-Mansiysk
Russian Federation
Russian Federation
Candidate of Sciences (Medicine), Associate Professor, Department of Hospital Therapy;
Head, Consultative and Diagnostic Hospital, Gastroenterologist
Е-mail: evg-sosnovskaya@yandex.ru
References
1. Pironi L., Arends J., Baxter J. et al. ESPEN Endorsed Recommendations. Definition and Classification of Intestinal Failure in Adults // Clin Nutr. 2015. № 34, Is. 2. Р. 171–180. DOI 10.1016/j.clnu.2014.08.017.
2. Weih S., Kessler M., Fonouni H., Golriz G., Hafezi M., Mehrabi A., Holland-Cunz S. Current Practice and Future Perspectives in the Treatment of Short Bowel Syndrome in Children – A Systematic Review // Langenbecks Arch Surg. 2012. Vol. 397, Is. 7. P. 1043–1051. DOI 10.1007/s00423-011-0874-8.
3. Sulkowski J. P., Minneci P. C. Management of Short Bowel Syndrome // Pathophysiology. 2014. Vol 21, Is. 1. Р. 111–118.
4. McGee D. C., Gould M. K. Preventing Complications of Central Venous Catheterization // N Engl J Med. 2003. Vol. 348, Is. 12. Р. 1123–1133. DOI 10.1056/NEJMra011883.
5. Revestive (Teduglutide) Summary of Product Characteristics. Shire Pharmaceuticals Ireland Limited, 2019.
6. Kocoshis S. A., Merritt R. J., Hill S. et al. Safety and Efficacy of Teduglutide in Pediatric Patients with Intestinal Failure Due to Short Bowel Syndrome: A 24-Week, Phase III Study // J Parenter Enteral Nutr. 2019. Vol. 44, Is. 4. P. 621–631. DOI 10.1002/jpen.1690.
7. Norsa L., Lambe C., Abi Abboud S. et al. The Colon as an Energy Salvage Organ for Children with Short Bowel Syndrome // Am J Clin Nutr. 2019. Vol. 109, Is. 4. P. 1112–1118. DOI 10.1093/ajcn/nqy367.
8. Joly F., Seguy D., Nuzzo A. et al. Six-month Outcomes of Teduglutide Treatment in Adult Patients with Short Bowel Syndrome with Chronic Intestinal Failure: A Real-World French Observational Cohort Study // Clin Nutr. 2020. Vol. 39, Is. 9. P. 2856–2862. DOI 10.1016/j.clnu.2019.12.019.
9. Schwartz L. K., O’Keefe S. J. D., Fujioka K. et al. Long-term Teduglutide for the Treatment of Patients with Intestinal Failure Associated with Short Bowel Syndrome // Clin Transl Gastroenterol. 2016. Vol. 7, Is. 2. Р. e142. DOI 10.1038/ ctg.2015.69.
10. Jeppesen P. B., Pertkiewicz M., Messing B. et al. Teduglutide Reduces Need for Parenteral Support Among Patients with Short Bowel Syndrome with Intestinal Failure // Gastroenterology. 2012. Vol. 143, Is. 6. Р. 1473–1481.e3. DOI 10.1053/j.gastro.2012.09.007.
11. Amiot A., Messing B., Corcos O., Panis A., Joly F. Determinants of Home Parenteral Nutrition Dependence and Survival of 268 Patients with Non Malignant Short Bowel Syndrome // Clin Nutr. 2013. Vol. 32, Is. 3. Р. 368–374. DOI 10.1016/j.clnu.2012.08.007.
Review
For citations:
Sosnovskaya E.V. MODERN OPPORTUNITIES OF PHARMACOTHERAPY FOR PATIENTS WITH SHORT BOWEL SYNDROME. Vestnik SurGU. Meditsina. 2021;(4 (50)):26-30. (In Russ.) https://doi.org/10.34822/2304-9448-2021-4-26-30
Views:
170
Email this article 
